J
Jazz Pharmaceuticals plc (JAZZ)
NMS – Real Time Price. Currency in USD
227.84
+4.23 (1.89%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
227.84
+4.23 (1.89%)
At close: May 12, 2026, 4:00 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 2.04 | 6.05 | 10 | |
| Quick ratio | 1.85 | 5.63 | 9.0 | |
| Debt to Equity | 1.20 | 0.30 | 6.0 | |
| Debt to Assets | 0.46 | 1.04 | 5.0 | |
| Interest coverage | 3.38 | -16.91 | 8.0 | |
| Weighted average score | 7.6 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 3.66B | 3.83B | 4.07B | 4.27B | 4.44B |
| Gross Profit | 2.52B | 2.79B | 3B | 3.11B | 3.23B |
| Operating Income | 720M | 659M | 727M | 751M | 849M |
| Net Income | -224M | 415M | 560M | -356M | 29M |
| EBITDA | 1.35B | 1.30B | 1.39B | 1.45B | 1.56B |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 5.73 | 173.88 | 7.5 |
| Next quarter | 2.31 | -22.38 | 2.0 |
| Current year | 5.29 | 197.68 | 7.5 |
| Next year | 7.29 | 2.35 | 4.0 |
| Weighted average score | 5.3 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -10.76 | 44.06 | -4.51 | 12.35 | 4.8 |
| Y/Y | 19.05 | 416.72 | 277.38 | -6.58 | 7.5 |
| 3y average | 5.26 | 52.2 | -2.34 | 2.87 | 5.0 |
| 5y average | 12.99 | -9.9 | 0.91 | 11.8 | 4.5 |
| Weighted average score | 5.5 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | Medium | 6.0 |
| Intangible assets | Wide | 8.0 |
| Switching costs | Medium | 7.0 |
| Network effect | None | 1.0 |
| Economies of scale | Medium | 6.0 |
| Weighted average score | 5.6 | |
Total debt $5.4B significantly exceeds cash reserves ($1.8B), raising financial stability concerns
Total current assets $4.6B exceed Total current liabilities $2.2B, highlighting excellent liquidity
Debt-to-equity ratio (1.2) is near the industry average, reflecting balanced leverage
Interest coverage ratio (3x) is sufficient but not particularly strong
The company generates positive free cash flow $388.5M, supporting its financial health